Supplemental Material

Supplemental Table S1. Patient inclusion/exclusion criteria

Inclusion
• Patients who are able to give written informed consent • Patients 50 years of age or older • Patients with a diagnosis of CNV secondary to AMD in the study eye, for which brolucizumab treatment was prescribed by the treating physician; this includes patients with lesion(s) with less than 50% hemorrhage, less than 50% fibrosis, and/or serous pigment epithelial detachment • Patients who have been previously treated with an anti-VEGF from which they were switched to brolucizumab • Patients who have received ≥3 injections of brolucizumab • Patients with BCVA score in the study eye between 19 and 78 letters inclusively, using ETDRS visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/400 at Screening)
Exclusion
• Patients with structural foveal damage, including advanced subretinal fibrosis or significant geographic atrophy involving the foveal centre (lack of morphological reserve) in the study eye • Patients with confounding severe ocular disease in the study eye – such as uncontrolled glaucoma, diabetic retinopathy likely to be visually significant within 2 years, cataract presumably requiring operation within 2 years – vitreous or pre-retinal hemorrhage obscuring the central macula, or presence of rhegmatogenous retinal detachment • Patients with polypoidal choroidal vasculopathy in the study eye

- Patients with active or suspected ocular or periocular infections in either eye
- Patients with active IOI in either eye
- Patients with physical or mental disabilities or who were being treated with other medications or procedures that prevented accurate vision testing

Supplemental Figure S1. Inclusion of patients submitted for review



[a] One patient developed moderate anterior and posterior IOI after his first dose. Brolucizumab was discontinued.

BCVA, best-corrected visual acuity; IOI, intraocular inflammation; nAMD, neovascular age-related macular degeneration

Supplemental Figure S2. Change in BCVA by treatment visit



	Baseline	2nd dose	3rd dose	4th dose	5th dose	6th dose
n	73	73	73	64	54	45
BCVA	57.7	60.3	62.4	62	62.3	64.4
SD	15.5	15.4	14.5	14.8	15.8	15.9

BCVA, best-corrected visual acuity; CI, confidence interval; ETDRS, Early Treatment Diabetic Retinopathy Study; SD, standard deviation

Supplemental Figure S3. Change in CRT by treatment visit



	Baseline	2nd dose	3rd dose	4th dose	5th dose	6th dose
n	73	73	73	64	54	45
CRT	301.2	266.5	260.7	274.3	273.6	263.1
SD	65.5	49.5	54.2	53.6	54.4	57.8

CI, confidence interval; CRT, central retinal thickness; SD, standard deviation